| 5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes |
Investors would do well to monitor broker-favored stocks like BTSG, BYON, ACDVF, DINO, and EBS for high returns. |
zacks.com |
2025-05-16 15:55:09 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions to Participate in Upcoming Investor Conferences |
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences: RBC Global Healthcare Conference (New York, New York) Fireside chat on Tuesday, May 20 at 3:35 pm ETVirtual attendees can participate via webcast Goldman Sachs Leveraged Finance Conference, May 29, 2025 (Dana Point, California) Benchmark's 5th Annual Healthcare House Call Virtual Investor Conference Presentation on Thursday, May 29 Jefferies Global Healthcare Conference (New York, New York) Presentation on Thursday, June 5 at 1:25 pm ETVirtual attendees can participate via webcast A replay of the presentations can be accessed from the Investors page of Emergent's website. |
globenewswire.com |
2025-05-14 11:32:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript |
Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Frank Vargo - Vice President, Assistant Treasurer Joe Papa - President and Chief Executive Officer Rich Lindahl - Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by. |
seekingalpha.com |
2025-05-08 02:01:58 |
Czytaj oryginał (ang.) |
| Emergent Biosolutions (EBS) Q1 Earnings Top Estimates |
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago. |
zacks.com |
2025-05-07 22:41:15 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Reports First Quarter 2025 Financial Results |
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year First Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior year First Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior year First Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior year Reaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health |
Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario |
globenewswire.com |
2025-05-01 21:07:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 |
GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. |
globenewswire.com |
2025-04-22 12:00:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Announces Stock Repurchase Program |
GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company's common stock on or before March 27, 2026. |
globenewswire.com |
2025-03-31 12:00:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 |
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan"). |
globenewswire.com |
2025-03-20 18:30:00 |
Czytaj oryginał (ang.) |
| Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg |
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada |
globenewswire.com |
2025-03-20 10:06:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International |
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately $36.5 million at closing, which is subject to customary post-closing adjustments. |
globenewswire.com |
2025-03-19 18:30:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products |
GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures (MCM) portfolio. |
globenewswire.com |
2025-03-18 10:00:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs |
GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring widespread opioid emergency preparedness as opioid overdose death rates continue to decline nationwide for the first time in five years.1 These efforts include working with organizations to expand access to NARCAN® Nasal Spray and educate the public on how to respond to an opioid overdose emergency. |
globenewswire.com |
2025-03-13 10:29:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates |
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one of Switzerland's next-generation vaccine companies and a member of the Swiss Rockets Ltd family of companies, today announced entry into an agreement for Emergent's strategic financial investment into Swiss Rockets Ltd, the parent company of Rocketvax Ltd, to support research, infrastructure development, and the expansion of Swiss Rockets' innovative biotechnology portfolio. This endeavor underscores Emergent's commitment to supporting Swiss Rockets' broader mission of pioneering breakthrough medical technologies. |
globenewswire.com |
2025-03-12 10:00:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International |
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines. |
globenewswire.com |
2025-03-10 11:14:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript |
Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ET Company Participants Frank Vargo - Assistant Treasurer Joseph Papa - President and Chief Executive Officer Richard Lindahl - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Nick Richitt - JPMorgan Brandon Folkes - Rodman & Renshaw Operator Good day, and thank you for standing by. Welcome to Emergent BioSolutions Inc. Fourth Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2025-03-03 21:58:36 |
Czytaj oryginał (ang.) |
| Emergent Biosolutions (EBS) Q4 Earnings Top Estimates |
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to loss of $0.77 per share a year ago. |
zacks.com |
2025-03-03 20:40:31 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results |
GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2024. |
globenewswire.com |
2025-03-03 18:23:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 |
Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025 Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025 |
globenewswire.com |
2025-02-18 10:55:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans |
GAITHERSBURG, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it is raising awareness of the Ready to Rescue initiative in New Orleans with pro football legend and NARCAN® Nasal Spray spokesperson, Emmitt Smith, as the city welcomes an anticipated 83,000 fans for the Big Game. For the past two years, Smith has traveled the country sharing his personal connection to the opioid epidemic to help reduce the stigma around accidental opioid poisonings and educate communities on how to save a life with NARCAN® Nasal Spray. Now, as New Orleans gears up to host one of the biggest events of the year, Emergent and Smith will continue these efforts to ensure the city is prepared to act in an opioid emergency, which can happen anytime, anywhere and to anyone. |
globenewswire.com |
2025-02-07 10:06:00 |
Czytaj oryginał (ang.) |
| Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) |
Africa CDC's support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo. |
globenewswire.com |
2025-01-16 10:00:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions: Stock Is A Likely Winner In 2025 |
Emergent BioSolutions has a sound turnaround strategy in place that is producing positive results. Emergent BioSolutions' cost-cutting efforts have the company on track for profitability in 2025. The undervaluation leaves plenty of room for the upside for the stock. |
seekingalpha.com |
2025-01-14 09:53:42 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals |
GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals' KLOXXADO® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is approved for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.1 This six-year agreement complements and strengthens Emergent's mission to protect, enhance, and save lives by helping to reduce opioid overdose deaths —providing compelling product options, combined with a commitment to increasing naloxone access, awareness, and education. |
globenewswire.com |
2025-01-14 09:30:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola |
GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, executed a contract modification for the second option period, valued at approximately $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga™ (ansuvimab-zykl). Ebanga™ is indicated for the treatment of infection caused by Zaire Ebola virus. |
globenewswire.com |
2025-01-13 11:27:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 |
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST. |
globenewswire.com |
2025-01-08 09:45:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed) |
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). |
globenewswire.com |
2025-01-08 09:30:00 |
Czytaj oryginał (ang.) |
| Why Emergent BioSolutions Stock Blasted Higher Today |
An analyst initiated coverage of Emergent BioSolutions (EBS 11.85%) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into the stock, ultimately sending it to a nearly 12% gain on the day. |
fool.com |
2024-12-30 19:26:09 |
Czytaj oryginał (ang.) |
| Emergent Stock Skyrockets 251% YTD: How to Play the Stock? |
The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism. |
zacks.com |
2024-12-27 11:35:18 |
Czytaj oryginał (ang.) |
| Why Emergent BioSciences Stock Plummeted Today |
Emergent BioSolutions (EBS -5.59%) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities. |
fool.com |
2024-12-03 20:47:11 |
Czytaj oryginał (ang.) |
| SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook |
SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under new CEO Joseph Papa provides an optimistic long-term outlook. Siga's financial stability is threatened by potential policy changes driven by the new U.S. government and TPOXX's uncertain efficacy against mpox. |
seekingalpha.com |
2024-12-02 19:49:22 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic |
Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats. |
seekingalpha.com |
2024-11-08 11:25:29 |
Czytaj oryginał (ang.) |
| Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 |
On Thursday, Emergent BioSolutions Inc. EBS stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa. |
benzinga.com |
2024-11-07 16:06:16 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for November 7th |
MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024. |
zacks.com |
2024-11-07 08:31:12 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript |
Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-07 00:08:17 |
Czytaj oryginał (ang.) |
| Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates |
Emergent Biosolutions (EBS) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $1.44 per share a year ago. |
zacks.com |
2024-11-06 21:26:29 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa |
GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa' (MOSA). The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial. |
globenewswire.com |
2024-11-06 18:49:00 |
Czytaj oryginał (ang.) |
| BlueOne Card Inc., Announces Definitive Agreement to Acquire Millennium EBS, Inc. in a $12 Million Deal |
BlueOne Card, Inc.(OTCQX: BCRD) a leading fintech provider of payment hub solutions and prepaid cards, announes an agreement to acquire Milennium EBS, Inc. |
globenewswire.com |
2024-10-25 23:18:00 |
Czytaj oryginał (ang.) |
| 5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades |
Investors should monitor stocks like AAL, ACDVF, EBS, BRY and CBRL for high returns. |
zacks.com |
2024-10-25 14:45:18 |
Czytaj oryginał (ang.) |
| Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS |
GREENBELT, Md., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Maryland has approved the following announcement of a proposed class action settlement that would benefit purchasers of Emergent BioSolutions Inc. common stock (NYSE: EBS): |
globenewswire.com |
2024-10-25 13:00:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 |
GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024. |
globenewswire.com |
2024-10-23 11:30:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic |
GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emergent is working with businesses to prepare for accidental opioid emergencies by ensuring workplaces, facilities, and hospitality venues, among many other locations, should consider being equipped with NARCAN® Nasal Spray. In March 2024, Emergent joined the ‘White House Challenge to Save Lives from Overdose', a nationwide call encouraging leaders to commit to increasing education of and access to life-saving opioid overdose reversal medications. |
globenewswire.com |
2024-10-08 21:32:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario |
Emergent BioSolutions is showing signs of a potential turnaround with strategic restructuring, cost-cutting, and securing significant contracts in public health preparedness. Despite a challenging Q2, the company raised its full-year revenue forecast and is focusing on improving operational efficiency and reducing debt. Emergent's involvement in global health crises, like mpox, and securing FDA approvals and contracts, positions it as a key player in biodefense. |
seekingalpha.com |
2024-10-04 13:48:28 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts |
GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA® (brincidofovir) to sustain the U.S. government's national preparedness posture against human smallpox. TEMBEXA® is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The order is valued at $67.4 million and executes procurement options CLIN0004A and CLIN0005A under Emergent's existing 10-year contract. |
globenewswire.com |
2024-09-26 12:05:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines |
On Wednesday, Emergent BioSolutions Inc. EBS said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and mpox product portfolio. |
benzinga.com |
2024-09-25 14:33:03 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts |
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 $185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 |
globenewswire.com |
2024-09-25 11:07:00 |
Czytaj oryginał (ang.) |
| Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation |
GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to resolve the previously disclosed securities class action litigation pending in the United States District Court for the District of Maryland (In re Emergent BioSolutions Inc. Security Litigation, No. 8:21-cv-00955-DLB). This lawsuit was originally filed in 2021. |
globenewswire.com |
2024-09-13 10:45:00 |
Czytaj oryginał (ang.) |